Live feed11:01:00·239dPRReleasevia QuantisnowTelitacicept Demonstrates Sustained Efficacy and Favorable Safety Profile in 48-Week China Phase 3 Open-Label Extension Generalized Myasthenia Gravis DataByQuantisnow·Wall Street's wire, on your screen.VOR· Vor Biopharma Inc.Health Care
